USH83H - Dental antiplaque agents and inhibitors of connective tissue destruction - Google Patents
Dental antiplaque agents and inhibitors of connective tissue destruction Download PDFInfo
- Publication number
- USH83H USH83H US06/710,771 US71077185A USH83H US H83 H USH83 H US H83H US 71077185 A US71077185 A US 71077185A US H83 H USH83 H US H83H
- Authority
- US
- United States
- Prior art keywords
- bis
- ureylenebis
- hydroxy
- naphthalenesulfonic acid
- disodium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002808 connective tissue Anatomy 0.000 title abstract description 18
- 230000006378 damage Effects 0.000 title abstract description 14
- 239000003112 inhibitor Substances 0.000 title abstract description 9
- 239000003795 chemical substances by application Substances 0.000 title description 5
- 230000002882 anti-plaque Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- 208000002064 Dental Plaque Diseases 0.000 claims abstract description 6
- 239000003085 diluting agent Substances 0.000 claims abstract description 6
- -1 salt cation Chemical class 0.000 claims description 212
- 238000002360 preparation method Methods 0.000 claims description 35
- 102000029816 Collagenase Human genes 0.000 claims description 34
- 108060005980 Collagenase Proteins 0.000 claims description 34
- 229960002424 collagenase Drugs 0.000 claims description 33
- HKWPUUYEGGDLJF-UHFFFAOYSA-N 4-hydroxynaphthalene-2-sulfonic acid Chemical class C1=CC=C2C(O)=CC(S(O)(=O)=O)=CC2=C1 HKWPUUYEGGDLJF-UHFFFAOYSA-N 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000006072 paste Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 150000001340 alkali metals Chemical class 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000006189 buccal tablet Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000007937 lozenge Substances 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 230000003239 periodontal effect Effects 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000000001 dental powder Substances 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 101150108015 STR6 gene Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 10
- 150000003839 salts Chemical class 0.000 abstract description 8
- 150000007513 acids Chemical class 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 200
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000004615 ingredient Substances 0.000 description 29
- 210000000515 tooth Anatomy 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 125000001841 imino group Chemical group [H]N=* 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
- 150000007945 N-acyl ureas Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002285 radioactive effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000011382 collagen catabolic process Effects 0.000 description 6
- 210000003298 dental enamel Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 150000002828 nitro derivatives Chemical class 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000000451 tissue damage Effects 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- SYMAOPXKWWZQIR-UHFFFAOYSA-N 8-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(O)=CC=CC2=C1 SYMAOPXKWWZQIR-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 102000035092 Neutral proteases Human genes 0.000 description 4
- 108091005507 Neutral proteases Proteins 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 241000194019 Streptococcus mutans Species 0.000 description 4
- 206010064996 Ulcerative keratitis Diseases 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 150000005690 diesters Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- PWJNDVAKQLOWRZ-UHFFFAOYSA-N 1-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=CC=C2C(O)=C(S(O)(=O)=O)C=CC2=C1 PWJNDVAKQLOWRZ-UHFFFAOYSA-N 0.000 description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229940124073 Complement inhibitor Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002442 collagenase inhibitor Substances 0.000 description 3
- 239000004074 complement inhibitor Substances 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000004210 tooth component Anatomy 0.000 description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- RXEQSXLXYITSGL-UHFFFAOYSA-N 1-[(2-amino-4-hydroxyphenyl)sulfonylamino]naphthalene-2-sulfonic acid Chemical compound NC1=CC(O)=CC=C1S(=O)(=O)NC1=C(S(O)(=O)=O)C=CC2=CC=CC=C12 RXEQSXLXYITSGL-UHFFFAOYSA-N 0.000 description 2
- OARNERIJXBUHLU-UHFFFAOYSA-N 1-dibenzofuran-2-yl-n,n-dimethylmethanamine Chemical compound C1=CC=C2C3=CC(CN(C)C)=CC=C3OC2=C1 OARNERIJXBUHLU-UHFFFAOYSA-N 0.000 description 2
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 description 2
- HLDSJEUWRUAPHF-UHFFFAOYSA-N 4-hydroxy-8-[[5-[[3-[(5-hydroxy-8-sulfonaphthalen-1-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=C(C=CC(O)=C5C=CC=4)S(O)(=O)=O)=CC=C3C)=CC=CC2=C1O HLDSJEUWRUAPHF-UHFFFAOYSA-N 0.000 description 2
- GDBANHJMXDZUNE-UHFFFAOYSA-N 5-hydroxynaphthalene-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2C(O)=CC=CC2=C1 GDBANHJMXDZUNE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 206010008642 Cholesteatoma Diseases 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 229940031956 chlorothymol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- YQLZOAVZWJBZSY-UHFFFAOYSA-N decane-1,10-diamine Chemical compound NCCCCCCCCCCN YQLZOAVZWJBZSY-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- AFTWNHIVQYAQCB-UHFFFAOYSA-M sodium;4-hydroxy-6-[(4-nitrophenyl)sulfonylamino]naphthalene-2-sulfonate Chemical compound [Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=CC2=CC=C1NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 AFTWNHIVQYAQCB-UHFFFAOYSA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 230000009092 tissue dysfunction Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AQMBYMISIHBQJX-UHFFFAOYSA-N 1-hydroxy-4-[[5-[[3-[(4-hydroxy-3-sulfonaphthalen-1-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=CC=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=CC=CC=C5C(O)=C(C=4)S(O)(=O)=O)=CC=C3C)=CC(S(O)(=O)=O)=C(O)C2=C1 AQMBYMISIHBQJX-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- LFOAKQQHKCCFNY-UHFFFAOYSA-N 2-cyclohexylnaphthalene Chemical class C1CCCCC1C1=CC=C(C=CC=C2)C2=C1 LFOAKQQHKCCFNY-UHFFFAOYSA-N 0.000 description 1
- SGBQUMZTGSQNAO-UHFFFAOYSA-N 2-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(O)=CC=C21 SGBQUMZTGSQNAO-UHFFFAOYSA-N 0.000 description 1
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical class [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
- UCAFWWJMJMEHBY-UHFFFAOYSA-N 3-hydroxy-4-[[4-[[4-[(2-hydroxy-3-sulfonaphthalen-1-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=CC=C2C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C4=CC=CC=C4C=C(C=3O)S(O)(=O)=O)C)C)=C(O)C(S(O)(=O)=O)=CC2=C1 UCAFWWJMJMEHBY-UHFFFAOYSA-N 0.000 description 1
- BBYCLLYPMSCGAL-UHFFFAOYSA-N 3-hydroxy-6-[[5-[[3-[(7-hydroxy-6-sulfonaphthalen-2-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C(O)=CC2=CC(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C=C5C=C(O)C(=CC5=CC=4)S(O)(=O)=O)=CC=C3C)=CC=C21 BBYCLLYPMSCGAL-UHFFFAOYSA-N 0.000 description 1
- RZMZJYAMZGWBLB-UHFFFAOYSA-N 3-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC=CC2=CC(O)=CC(S(O)(=O)=O)=C21 RZMZJYAMZGWBLB-UHFFFAOYSA-N 0.000 description 1
- CQVCNDRLEMAPBX-UHFFFAOYSA-N 4-hydroxy-1-[[4-[[4-[(4-hydroxy-2-sulfonaphthalen-1-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C12=CC=CC=C2C(O)=CC(S(O)(=O)=O)=C1NS(=O)(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(S(=O)(=O)NC=2C3=CC=CC=C3C(O)=CC=2S(O)(=O)=O)C=C1 CQVCNDRLEMAPBX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XUSMKYNDSVCOIS-UHFFFAOYSA-N 4-hydroxy-3-[[4-[[4-[(1-hydroxy-3-sulfonaphthalen-2-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=CC=C2C=C(S(O)(=O)=O)C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C(=CC4=CC=CC=C4C=3O)S(O)(=O)=O)C)C)=C(O)C2=C1 XUSMKYNDSVCOIS-UHFFFAOYSA-N 0.000 description 1
- LHTLBZFXWJIVDY-UHFFFAOYSA-N 4-hydroxy-5-[[3-[[3-[(8-hydroxy-6-sulfonaphthalen-1-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(NS(=O)(=O)C=3C=CC=C(C=3)NC(=O)NC=3C=CC=C(C=3)S(=O)(=O)NC=3C=CC=C4C=C(C=C(C=34)O)S(O)(=O)=O)=CC=CC2=C1 LHTLBZFXWJIVDY-UHFFFAOYSA-N 0.000 description 1
- REULIRSMJJCFSU-UHFFFAOYSA-N 4-hydroxy-6-[[4-[[4-[(8-hydroxy-6-sulfonaphthalen-2-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(O)C2=CC(NS(=O)(=O)C3=CC=C(C=C3)NC(=O)NC3=CC=C(C=C3)S(=O)(=O)NC3=CC=C4C=C(C=C(C4=C3)O)S(O)(=O)=O)=CC=C21 REULIRSMJJCFSU-UHFFFAOYSA-N 0.000 description 1
- MXWJZYGLFVZSQN-UHFFFAOYSA-N 4-hydroxy-7-[[3-[[3-[(5-hydroxy-7-sulfonaphthalen-2-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(NS(=O)(=O)C=3C=CC=C(C=3)NC(=O)NC=3C=CC=C(C=3)S(=O)(=O)NC=3C=C4C=C(C=C(C4=CC=3)O)S(O)(=O)=O)=CC=C21 MXWJZYGLFVZSQN-UHFFFAOYSA-N 0.000 description 1
- HGWQOFDAUWCQDA-UHFFFAOYSA-N 4-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(O)=CC=C(S(O)(=O)=O)C2=C1 HGWQOFDAUWCQDA-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- JVWOCQZTOMMPAO-UHFFFAOYSA-N 5-hydroxy-2-[[3-[[3-[(5-hydroxy-1-sulfonaphthalen-2-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound OC1=CC=CC2=C(S(O)(=O)=O)C(NS(=O)(=O)C=3C=CC=C(C=3)NC(=O)NC=3C=CC=C(C=3)S(=O)(=O)NC=3C(=C4C=CC=C(C4=CC=3)O)S(O)(=O)=O)=CC=C21 JVWOCQZTOMMPAO-UHFFFAOYSA-N 0.000 description 1
- UBBRMWCXDLVOHQ-UHFFFAOYSA-N 5-hydroxy-4-[[3-[[3-[(8-hydroxy-4-sulfonaphthalen-1-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(NS(=O)(=O)C=3C=CC=C(C=3)NC(=O)NC=3C=CC=C(C=3)S(=O)(=O)NC=3C=CC(=C4C=CC=C(C=34)O)S(O)(=O)=O)=CC=C(S(O)(=O)=O)C2=C1 UBBRMWCXDLVOHQ-UHFFFAOYSA-N 0.000 description 1
- MHHAEVMDQRHUEL-UHFFFAOYSA-N 5-hydroxy-4-[[4-[[4-[(8-hydroxy-4-sulfonaphthalen-1-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C4=C(O)C=CC=C4C(=CC=3)S(O)(=O)=O)C)C)=CC=C(S(O)(=O)=O)C2=C1 MHHAEVMDQRHUEL-UHFFFAOYSA-N 0.000 description 1
- AEQZJFBOQRHADZ-UHFFFAOYSA-N 5-hydroxy-4-[[4-[[4-[(8-hydroxy-4-sulfonaphthalen-1-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(NS(=O)(=O)C3=CC=C(C=C3)NC(=O)NC3=CC=C(C=C3)S(=O)(=O)NC=3C=CC(=C4C=CC=C(C=34)O)S(O)(=O)=O)=CC=C(S(O)(=O)=O)C2=C1 AEQZJFBOQRHADZ-UHFFFAOYSA-N 0.000 description 1
- FTLAKRNIJGTMLS-UHFFFAOYSA-N 5-hydroxy-4-[[5-[[3-[(8-hydroxy-4-sulfonaphthalen-1-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=C(O)C=CC=C5C(=CC=4)S(O)(=O)=O)=CC=C3C)=CC=C(S(O)(=O)=O)C2=C1 FTLAKRNIJGTMLS-UHFFFAOYSA-N 0.000 description 1
- CWMJBHKOGWDDBK-UHFFFAOYSA-N 5-hydroxy-6-[[3-[[3-[(1-hydroxy-6-sulfonaphthalen-2-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=CC2=CC(S(O)(=O)=O)=CC=C2C(O)=C1NS(=O)(=O)C1=CC=CC(NC(=O)NC=2C=C(C=CC=2)S(=O)(=O)NC=2C(=C3C=CC(=CC3=CC=2)S(O)(=O)=O)O)=C1 CWMJBHKOGWDDBK-UHFFFAOYSA-N 0.000 description 1
- SJSUMBYOZZLPOG-UHFFFAOYSA-N 5-hydroxy-6-[[4-[[4-[(1-hydroxy-5-sulfonaphthalen-2-yl)sulfamoyl]phenyl]carbamoylamino]phenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=CC2=C(S(O)(=O)=O)C=CC=C2C(O)=C1NS(=O)(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(S(=O)(=O)NC=2C(=C3C=CC=C(C3=CC=2)S(O)(=O)=O)O)C=C1 SJSUMBYOZZLPOG-UHFFFAOYSA-N 0.000 description 1
- QFHTVLYDCKHLKP-UHFFFAOYSA-N 5-hydroxy-6-[[4-[[4-[(1-hydroxy-6-sulfonaphthalen-2-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=CC2=C(O)C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C(=C4C=CC(=CC4=CC=3)S(O)(=O)=O)O)C)C)=CC=C21 QFHTVLYDCKHLKP-UHFFFAOYSA-N 0.000 description 1
- WWDBMJHDHSRLFI-UHFFFAOYSA-N 5-hydroxy-6-[[5-[[3-[(1-hydroxy-6-sulfonaphthalen-2-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=CC2=C(O)C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C(=C5C=CC(=CC5=CC=4)S(O)(=O)=O)O)=CC=C3C)=CC=C21 WWDBMJHDHSRLFI-UHFFFAOYSA-N 0.000 description 1
- NZWCWIRWGLAFNK-UHFFFAOYSA-N 5-hydroxy-7-[[4-[[4-[(4-hydroxy-7-sulfonaphthalen-2-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=CC2=CC(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C=C4C=C(C=CC4=C(O)C=3)S(O)(=O)=O)C)C)=CC(O)=C21 NZWCWIRWGLAFNK-UHFFFAOYSA-N 0.000 description 1
- UJXMFUPWHWMVTH-UHFFFAOYSA-N 5-hydroxy-8-[[5-[[3-[(4-hydroxy-8-sulfonaphthalen-1-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=CC(S(O)(=O)=O)=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=C(C=CC=C5C(O)=CC=4)S(O)(=O)=O)=CC=C3C)=CC=C(O)C2=C1 UJXMFUPWHWMVTH-UHFFFAOYSA-N 0.000 description 1
- YLKCHWCYYNKADS-UHFFFAOYSA-N 5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(O)=CC=CC2=C1S(O)(=O)=O YLKCHWCYYNKADS-UHFFFAOYSA-N 0.000 description 1
- HBZVNWNSRNTWPS-UHFFFAOYSA-N 6-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(O)C2=CC(N)=CC=C21 HBZVNWNSRNTWPS-UHFFFAOYSA-N 0.000 description 1
- OJKPEKNXQOTCNQ-UHFFFAOYSA-N 6-hydroxy-4-[[5-[[3-[(7-hydroxy-4-sulfonaphthalen-1-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound C1=C(O)C=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=CC(O)=CC=C5C(=CC=4)S(O)(=O)=O)=CC=C3C)=CC=C(S(O)(=O)=O)C2=C1 OJKPEKNXQOTCNQ-UHFFFAOYSA-N 0.000 description 1
- SCOSSUFXFMVRJQ-UHFFFAOYSA-M 6-hydroxynaphthalene-1-sulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC2=CC(O)=CC=C21 SCOSSUFXFMVRJQ-UHFFFAOYSA-M 0.000 description 1
- VVPHSMHEYVOVLH-UHFFFAOYSA-N 6-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=CC2=CC(O)=CC=C21 VVPHSMHEYVOVLH-UHFFFAOYSA-N 0.000 description 1
- HKKGXMYOCBMTFZ-UHFFFAOYSA-N 7-hydroxy-4-[[4-[[4-[(6-hydroxy-3-sulfonaphthalen-1-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound OC1=CC=C2C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C4=CC=C(O)C=C4C=C(C=3)S(O)(=O)=O)C)C)=CC(S(O)(=O)=O)=CC2=C1 HKKGXMYOCBMTFZ-UHFFFAOYSA-N 0.000 description 1
- GAIBJMSMBPTLBL-UHFFFAOYSA-N 7-hydroxy-4-[[4-[[4-[(6-hydroxy-4-sulfonaphthalen-1-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound OC1=CC=C2C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C4=CC=C(O)C=C4C(=CC=3)S(O)(=O)=O)C)C)=CC=C(S(O)(=O)=O)C2=C1 GAIBJMSMBPTLBL-UHFFFAOYSA-N 0.000 description 1
- HGFJEWXICYHIJX-UHFFFAOYSA-N 7-hydroxy-5-[[4-[[4-[(3-hydroxy-6-sulfonaphthalen-1-yl)sulfamoyl]-2-methylphenyl]carbamoylamino]-3-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C4=CC=C(C=C4C=C(O)C=3)S(O)(=O)=O)C)C)=CC(O)=CC2=C1 HGFJEWXICYHIJX-UHFFFAOYSA-N 0.000 description 1
- HUYJTJXLNBOVFO-UHFFFAOYSA-N 7-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(O)=CC=C21 HUYJTJXLNBOVFO-UHFFFAOYSA-N 0.000 description 1
- OZGUUAIBZPOQTN-UHFFFAOYSA-N 8-hydroxy-4-[[5-[[3-[(5-hydroxy-3-sulfonaphthalen-1-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-2-sulfonic acid Chemical compound C1=CC=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=CC=CC(O)=C5C=C(C=4)S(O)(=O)=O)=CC=C3C)=CC(S(O)(=O)=O)=CC2=C1O OZGUUAIBZPOQTN-UHFFFAOYSA-N 0.000 description 1
- MRZNYCPTAYGRSJ-UHFFFAOYSA-N 8-hydroxy-5-[[5-[[3-[(4-hydroxy-5-sulfonaphthalen-1-yl)sulfamoyl]-4-methylphenyl]carbamoylamino]-2-methylphenyl]sulfonylamino]naphthalene-1-sulfonic acid Chemical compound N(C(=O)NC=1C=C(C(=CC=1)C)S(=O)(=O)NC1=C2C=CC=C(C2=C(C=C1)O)S(=O)(=O)O)C=1C=C(C(=CC=1)C)S(=O)(=O)NC1=C2C=CC=C(C2=C(C=C1)O)S(=O)(=O)O MRZNYCPTAYGRSJ-UHFFFAOYSA-N 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical class CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- VNGAWIXVBDLHNM-UHFFFAOYSA-N C1=C(O)C=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=CC(O)=CC(=C5C=CC=4)S(O)(=O)=O)=CC=C3C)=CC=CC2=C1S(O)(=O)=O Chemical compound C1=C(O)C=C2C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C5=CC(O)=CC(=C5C=CC=4)S(O)(=O)=O)=CC=C3C)=CC=CC2=C1S(O)(=O)=O VNGAWIXVBDLHNM-UHFFFAOYSA-N 0.000 description 1
- BYISVCYGQZFDOU-UHFFFAOYSA-N C1=C(S(O)(=O)=O)C=CC2=CC(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C=C5C=CC(=CC5=C(O)C=4)S(O)(=O)=O)=CC=C3C)=CC(O)=C21 Chemical compound C1=C(S(O)(=O)=O)C=CC2=CC(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C=C5C=CC(=CC5=C(O)C=4)S(O)(=O)=O)=CC=C3C)=CC(O)=C21 BYISVCYGQZFDOU-UHFFFAOYSA-N 0.000 description 1
- FOLBLMYWGRULJG-UHFFFAOYSA-N C1=CC=C(S(O)(=O)=O)C2=C(O)C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C(=C5C(=CC=CC5=CC=4)S(O)(=O)=O)O)=CC=C3C)=CC=C21 Chemical compound C1=CC=C(S(O)(=O)=O)C2=C(O)C(NS(=O)(=O)C3=CC(NC(=O)NC=4C=C(C(C)=CC=4)S(=O)(=O)NC=4C(=C5C(=CC=CC5=CC=4)S(O)(=O)=O)O)=CC=C3C)=CC=C21 FOLBLMYWGRULJG-UHFFFAOYSA-N 0.000 description 1
- YISZKUNRHMZLHA-UHFFFAOYSA-N C1=CC=C(S(O)(=O)=O)C2=C(O)C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C(=C4C(=CC=CC4=CC=3)S(O)(=O)=O)O)C)C)=CC=C21 Chemical compound C1=CC=C(S(O)(=O)=O)C2=C(O)C(NS(=O)(=O)C=3C=C(C(=CC=3)NC(=O)NC=3C(=CC(=CC=3)S(=O)(=O)NC=3C(=C4C(=CC=CC4=CC=3)S(O)(=O)=O)O)C)C)=CC=C21 YISZKUNRHMZLHA-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004858 Canada balsam Substances 0.000 description 1
- 240000005209 Canarium indicum Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- NVTRPRFAWJGJAJ-UHFFFAOYSA-L EDTA monocalcium salt Chemical compound [Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O NVTRPRFAWJGJAJ-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 241001443715 Fusarium oxysporum f. sp. conglutinans Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003610 anti-gingivitis Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000004862 elemi Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- 239000002690 trypanocidal agent Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
Definitions
- the present invention relates to certain [ureylenebis(phenylenesulfonylimino)]bis[hydroxynaphthalenesulfonic acids] and salts thereof, which are novel compounds useful as dental antiplaque agents and as inhibitors of connective tissue destruction.
- connective tissue refers to a matrix of at least three protein molecules, namely collagen, proteoglycan and elastin. These molecules play an important role in the structural integrity of normal tissues. Collagen, the most abundant protein in the body occupies a central position in the connective tissue matrix [Biochemistry of Collagen, Ed. G. N. Ramachandran and A. H. Reddi, Academic Press, New York (1976); P. Bornstein, Ann. Rev. Biochem., 43, 567 (1974); J. Fessler and L. Fessler, Ann. Rev. Biochem., 47, 129 (1978)].
- Collagen is, for example, the main structural component of the oral tissue (periodontal ligament, alveolar bone, gingiva, and cementum) [Fullmer, et al., J. Dental Research, 48, 646 (1969)]. Collagen amounts to 40% of cartilage protein, 90% of bone protein, and over 90% of dry dermis.
- Articular cartilage the resilient tissue that covers the articulating extremities in synovial joints, consists of collagen fibers that are intimately meshed in a hydrated gel of proteoglycan.
- Proteoglycan as it exists in cartilage, is a molecule in which sulfated polysaccharide chains are covalently linked to a protein backbone [Dynamics of Connective Tissue Macromolecules, Ed. P. M. Burleigh and A. R. Poole, North Holland, Amsterdam (1975)].
- Elastin is a major connective tissue component of pulmonary structure [Elastin and Elastic Tissue, Ed. L. B. Sandberg, W. R. Gray, and C. Franzblau, Plenum Press, New York (1977)].
- the breadkown of elastin of pulmonary connective tissue is considered the primary event in pulmonary emphysema [A. Janoff in "Proteases and Biological Control", Cold Spring Harbor Conference on Cell Proliferation, 2, 603 (1975)].
- Degradation of fibrous collagen is initiated by a combination of neutral proteases and tissue collagenase as an integral part of a complex immunopathological process which results in the loss of collagen from normal tissue.
- cellular mechanisms maintain a careful balance between the rates of collagen synthesis and degradation.
- the ensuing elevated levels of neutral proteases and collagenase can result in rapid collagen degradation and tissue dysfunction.
- the generated elevated levels of neutral proteases and collagenase in the gingival crevicular fluid rapidly degrade the fibrous collagen supporting the teeth.
- Periodontal pockets result ultimately from collagen degradation and, as these pockets deepen, support of the teeth is lost and alveolar bone is resorbed [K. Ohlsson, I.
- Such substances include, for example, ethylenediaminetetraacetate, 1,10-phenanthroline, cysteine, dithiothreitol and sodium auriothiomalate [D. E. Woolley, R. W. Glanville, D. R. Roberts, and J. M. Evanson, Biochem. J., 169, 265 (1978); S. Seifter and E. Harper, Chap. 18, "The Collagenases” in The Enzymes (3rd. Edition), 3, 649-697, Ed. by P. D. Boyer, Academic Press, N.Y. (1971)].
- Naturally occurring collagenase inhibitors include the serum components ⁇ 2 -macroglobulin and ⁇ 1 -anticollagenase [D. E. Woolley, R. W. Glanville, D. R. Roberts and J. M. Evanson, Biochem. J., 169, 265 (1978)].
- dental plaque on teeth is considered to be a precursor to dental caries, gingivitis and periodontal disease. Therefore methods and compositions useful for the prevention or inhibition of dental plaque formation on teeth are considered to be of major potential therapeutic importance.
- Dental caries which always begin on the external surfaces of the teeth may be initiated by oral acidogenic bacteria which include Lactobacillis acidophilus and Streptococci, e.g., Streptococcus mutans, and yeasts capable of producing a pH of 5.5 or lower. Fermentable dietary carbohydrates serve as substrates for the microbial enzyme systems leading to the production of acidic metabolic products such as lactic, acetic, formic and butyric acids. Adherence of cariogenic bacteria such as Streptococcus mutans, and the like, to tooth enamel and their aggregation and colonization to dental plaque are prerequisites to the formation of carious lesions.
- oral acidogenic bacteria which include Lactobacillis acidophilus and Streptococci, e.g., Streptococcus mutans, and yeasts capable of producing a pH of 5.5 or lower. Fermentable dietary carbohydrates serve as substrates for the microbial enzyme systems leading to the production of acidic metabolic products such as lactic, acetic, formic
- Colonization on the tooth surface may serve as an area favorable to the production of the acidic metabolic products hereinabove described, providing protection from the buffering action of the saliva and causing the dissolution of the enamel in the vicinity of the plaque area resulting in decalcification.
- Some proteolytic action on the organic structure may also take place.
- Gingivitis which is an inflammation of the gums characterized by congested, red and swollen gingivae, frequently may occur due to dental calculus as the sole cause.
- Periodontitis the most common form of periodontal disease is characterized by inflammatory tissue changes usually due to local irritation, which local causes include irritation resulting from calcareous deposits on the teeth.
- dental caries can be prevented by eliminating cariogenic bacteria, especially Streptococcus mutans, from the mouth or by increasing the resistance of enamel to acid and/or the adherence of S. mutans to its surface.
- Fluoride a known anticaries agent, is known to protect human tooth enamel from dissolution. Mechanistic studies indicate that fluoride binds to enamel and is incorporated into the hydroxyapatite fraction of the enamel. The resulting fluoroapatite is relatively resistant to acid.
- U.S. Pat. No. 2,687,436 discloses substituted 3-(2-naphthyl)cyclohexanes useful in the treatment of collagen diseases.
- British Pat. Nos. 856,357 and 1,246,141 disclose 2-aryl-hexahydro-quinolizines and 1-hydroxylpraline derivatives, respectively, useful for treating diseases affecting connective tissue.
- the closest known structurally related compound to those of the present invention and disclosed as having collagenase inhibiting activity is found in Thromb. Res. 1977, 10(4), 605-11 wherein the trypanocidal agent trypan blue is reported as inhibiting the activity of collagenase, or a proteinase contaminant in the collagenase preparation.
- While some compounds may inhibit the destructive effect of collagenase on connective tissue by acting directly on collagenase itself, other compounds may inhibit such destruction by coating, binding or competing with sights on the connective tissue in such a manner as to prevent collagenase from attacking it.
- the present invention is not to be restricted or limited to any particular mechanism or mode of action. Suffice it to say, that the compounds of this invention have utility as inhibitors of connective tissue destruction albeit in whatever manner or mode.
- This invention is concerned with the novel C-substituted naphthalenemonosulfonic ureides which may be represented by Formula I: ##STR1## wherein A is hydrogen or a pharmaceutically acceptable salt cation; B is hydrogen, lower(C 1 -C 6 )alkanoyl or alkali metal; and R is hydrogen or lower(C 1 -C 3 )alkyl.
- a preferred form of the present invention is concerned with those ureides wherein neither the R nor the NH--group are ortho to the fixed position of the sulfoxamido group (--NHSO 2 --) in the bridgehead and such ureides may be represented by Formula II, III and IV: ##STR2## wherein A, B and R are as defined with reference to Formula I.
- salt cation an alkali metal; an alkaline earth metal; ammonium; primary amine, e.g., ethylamine; secondary amine, e.g., diethylamine or diethanolamine; tertiary amine, e.g., pyridine, triethylamine or 2-dimethylaminomethyldibenzofuran; aliphatic amine, e.g., decamethylenediamine; or aromatic amine.
- primary amine e.g., ethylamine
- secondary amine e.g., diethylamine or diethanolamine
- tertiary amine e.g., pyridine, triethylamine or 2-dimethylaminomethyldibenzofuran
- aliphatic amine e.g., decamethylenediamine
- aromatic amine aromatic amine
- novel [ureylenebis(phenylenesulfonylimino)]-bis[hydroxynaphthalenesulfonic acids] and salts thereof of the present invention have been found to bind to various tooth components and also to inhibit the deposition of dental plaque onto the teeth of mammals.
- the [ureylenebis(phenylenesulfonylimino)]bis-[hydroxynaphthalenesulfonates] of this invention are substantially soluble in water or water/organic solvent vehicles and are applied to teeth by various means from different dentifrice formulations.
- Representative compounds encompassed within this invention include, for example, 6,6'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(p-phenylenesulfonylimino) ]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(3-methyl-4,1-phenylenesulfonyl)imino]]bis [4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino) ]bis[5-hydroxy-1-
- This invention is also concerned with a method of inhibiting connective tissue destruction in a warm-blooded animal which comprises administering to said animal an effective inhibiting amount of a compound encompassed within Formulae I, II, III or IV.
- this invention is concerned with a method of inhibiting the degradation sequelae of collagenase activity in a body fluid, such as crevicular fluid, synovial fluid and the like, which comprises subjecting body fluid collagenase to the action of an effective collagenase inhibiting amount of a compound encompassed within the above formulae.
- Body fluid can include blood, plasma, serum, synovial fluid, crevicular fluid, ocular fluid, etc., containing collagenase.
- the method of use aspect of this invention is further concerned with a method of inhibiting the action of collagenase in a warm-blooded animal which comprises internally administering to said animal an effective collagenase inhibiting amount of a compound encompassed with the above formulae.
- a further method of use aspect of the present invention is concerned with a method for inibiting and preventing the deposition of dental plaque onto the surfaces of the teeth of warm-blooded animals, mainly, the deposition of dental plaque onto human teeth, which comprises applying the potential plaque barrier [ureylenebis-(phenylenesulfonylimino)]bis[hydroxynaphthalenesulfonic acids] and salts thereof of the present invention, which are substantially soluble in water or water/organic solvent vehicles, in the form of various dentifrice formulations such as pastes, ointments, creams, lotions, gels, powders, buccal tablets, lozenges, tooth paste, rinses and the like or other oral hygienic procedures.
- the potential plaque barrier [ureylenebis-(phenylenesulfonylimino)]bis[hydroxynaphthalenesulfonic acids] and salts thereof of the present invention, which are substantially soluble in water or water/organic solvent vehicles, in the form of various dentifrice
- the compounds of the present invention find utility as inhibitors of connective tissue destruction or as collagenase inhibitors in body fluids, as such they may be useful in ameliorating or preventing those pathological reactions resulting from the functioning of collagenase, and in the therapeutic treatment of warm-blooded animals having connective tissue disorders such as periodontal diseases and diseases of the teeth, osteoporosis, osteolysis, Paget's disease, hyperparathyroidism of renal failure, rheumatoid arthritis, septic arthritis, osteoarthritis, gout, acute synovitis, scleroderma, posoriasis, epidermolysis bullosa, keloids, blisters, cholesteatoma of the ear, and corneal ulceration.
- the compounds of the present invention may also be useful in those pathological states where excessive activity of neutral proteases causes tissue damage.
- the compounds of the present invention may be prepared according to the following Flowchart A. ##STR3##
- a substituted-amino-naphthalenesulfonic acid (1) is dissolved in water, made basic with any suitable base such as, for example, an alkali acetate or alkali metal carbonate reacted with an alkali acetate such as sodium acetate, filtered and reacted under an inert atmosphere, e.g., nitrogen, with an excess of substituted nitrobenzenesulfonyl chloride (2), giving a substituted nitrobenzenesulfonamido-substituted -naphthalenesulfonic acid (3).
- This nitro derivative (3) is then hydrogenated in the presence of a suitable catalyst, giving the corresponding amine derivative (4).
- the amine (4) is dissolved in a basic solution of pyridine and water and then phosgenated.
- the final ureide product (5) is extracted from conventional organic solvents such as ethanol or ether.
- the resulting compound may be converted to its salt in a known manner.
- a suspension of 2.0 g of 4-hydroxy-6-p-nitrobenzenesulfonamido-2-naphthalenesulfonic acid sodium salt in about 200 ml of water was converted to a solution by the addition of sufficient 10N sodium hydroxide.
- the solution was filtered and to the filtrate was added 2.8 g of 10% palladium-on-carbon catalyst.
- the mixture was hydrogenated in a Parr shaker until no further hydrogen was taken up.
- the reaction mixture was filtered through diatomaceous earth and the filter was washed with water.
- the filtrate and wash were combined and acidified with concentrated hydrochloric acid and gave a gum.
- the gum was separated and triturated with ethanol. Filtration gave 3.0 g of the desired product as a grey solid.
- a 4.0 g amount of 4-hydroxy-6-sulfanilamido-2-naphthalenesulfonic acid (prepared as described in Example 1) was suspended in 90 ml of water and 2.14 ml of 5N sodium hydroxide was added to yield a solution. The solution was filtered and 11.0 ml of pyridine was added to the filtrate. Phosgene was passed into the filtrate at 18°-28° C. (ice bath cooling) with vigorous stirring giving a gummy material. Phosgenation was continued until the mixture was strongly acidic. Then 5N sodium hydroxide was added again until solution was achieved, 11 ml of pyridine was added and the mixture was rephosgenated.
- the supernatant was decanted and the residual gummy material was triturated with water.
- the resulting solid was collected by filtration and air dried.
- the solid was triturated with ethanol, filtered, and washed with ethanol, then ether and dried to give 3.0 g of a pink solid.
- the solid was suspended in water and 5N sodium hydroxide was added to achieve solution at a total volume of about 30 ml. This solution was added with vigorous stirring to ethanol:ether (2:1). The precipitate formed was collected by filtration, washed with ether and dried and gave 1.75 g of pink solid.
- the final tablet will weigh about 325 mg. and may be compressed into buccal tablets in flat faced or any other tooling shape convenient for buccal administration.
- the ingredients are compressed into 5/8" flat based lozenge tooling. Other shapes may also be utilized.
- the compounds of this invention may be administered internally to a warm-blooded animal to inhibit connective tissue destruction or collagenase, such inhibition being useful in the amelioration or prevention of those reactions causing connective tissue damage.
- a range of doses may be employed depending on the mode of administration, the condition being treated and the particular compound being used. For example, for intravenous or subcutaneous use from about 5 to about 50 mg/kg/day, or every six hours for more rapidly excreted salts, may be used. For intra-articular use for large joints such as the knee, from about 2 to about 20 mg/joint per week may be used, with proportionally smaller doses for smaller joints.
- the dosage range is to be adjusted to provide optimum therapeutic response in the warm-blooded animal being treated.
- the amount of compound administered can vary over a wide range to provide from about 1.5 mg/kg to about 100 mg/kg of body weight of animal per day.
- the usual daily dosage for a 70 kg subject may vary from about 100 mg to about 3.5 g.
- Unit doses can contain from about 0.5 mg to about 500 mg.
- sodium salts of the acids of the invention are suitable for parenteral use
- other salts may also be prepared, such as those of primary amines, e.g., ethylamine; secondary amines, e.g., diethylamine or diethanolamine; tertiary amines, e.g., pyridine or triethylamine or 2-dimethylaminomethyldibenzofuran, aliphatic diamines, e.g., decamethylenediamine; and aromatoic diamines, can be prepared.
- primary amines e.g., ethylamine
- secondary amines e.g., diethylamine or diethanolamine
- tertiary amines e.g., pyridine or triethylamine or 2-dimethylaminomethyldibenzofuran
- aliphatic diamines e.g., decamethylenediamine
- aromatoic diamines can be
- alkali metals such as potassium and lithium; of ammonia; and of the alkaline earth metals, such as calcium or magnesium, may be employed. It will be apparent, therefore, that these salts embrace, in general, derivatives of salt-forming cations.
- the compounds of this invention may be administered in the form of conventional pharmaceutical compositions.
- Such compositions may be formulated so as to be suitable for oral or parenteral administration.
- the active ingredient may be combined in admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, i.e., oral or parenteral.
- the compounds of this invention can be used in compositions such as tablets.
- the principle active ingredient is mixed with conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums, or similar materials as non-toxic pharmaceutically acceptable diluents or carriers.
- the tablets or pills of the novel compositions can be laminated or otherwise compounded to provide a dosage form affording the advantage of prolonged or delayed action or predetermined successive action of the enclosed medication.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids or mixtures of polymeric acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate and the like.
- a particularly advantageous enteric coating comprises a styrene maleic acid copolymer together with known materials contributing to the enteric properties of the coating.
- the tablet or pill may be colored through the use of an appropriate nontoxic dye, so as to provide a pleasing appearance.
- liquid forms in which the novel compositions of the present invention may be incorporated for administration include suitable flavored emulsions with edible oils, such as, cottonseed oil, sesame oil, coconut oil, peanut oil, and the like, as well as elixirs and similar pharmaceutical vehicles.
- suitable flavored emulsions with edible oils such as, cottonseed oil, sesame oil, coconut oil, peanut oil, and the like
- Sterile suspensions or solutions can be prepared for parenteral use. Isotonic preparations containing suitable preservatives are also desirable for injection use.
- the compounds of the present invention may also be administered topically in the form of ointments, creams, lotions and the like, suitable for the treatment of connective tissue dependent dermatological disorders.
- the compounds of the present invention may be administered in the form of dental pastes, ointments, buccal tablets and other compositions suitable for application periodontally for the treatment of periodontitis and related diseases of the oral cavity.
- dosage form as described herein refers to physically discrete units suitable as unitary dosage for warm-blooded animal subjects, each unit containing a predetermined quantity of active component calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle.
- the specification for the novel dosage forms of this invention are indicated by characteristics of the active component and the particular therapeutic effect to be achieved or the limitations inherent in the art of compounding such an active component for therapeutic use in warm-blooded animals as disclosed in this specification.
- suitable oral dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, cachets, teaspoonfuls, dropperfuls, ampules, vials, segregated multiples of any of the foregoing and other forms as herein described.
- a collagenase assay was performed by a modification of the method of Harper, et al., Biochem., 10, 3035 (1971). In a typical assay (total volume of 0.45 ml), 100 ⁇ l of the activated enzyme was added to the 14 C-labeled collagen fibrils (250 ⁇ l) followed by 100 ⁇ l of 50 mM cacodylate, pH 7.4, containing 5 mM calcium chloride. After incubation at 37° C. for 16 hours, the tubes were centrifuged in a Beckman microfuge for five minutes at full speed. An aliquot (200 ⁇ l) of the supernatant, representing collagenase digestion products of the fibril, was assayed for radioactivity. The effect of the test compound on collagen degradation by collagenase was examined as follows:
- Varying concentrations of the test compound (in distilled water) were added to the assay tubes containing active collagenase (total volume 450 ⁇ l) and after 16 hours the amount of radioactivity in the supernatant was determined. Appropriate blanks and trypsin controls were run in parallel.
- Table I shows that a representative compound of the invention possesses the ability to inhibit collagen degradation.
- the result is expressed as an ID 50 collagenase value which represents a ratio of the weight ( ⁇ g) of the representative compound required for 50% inhibition of collagenase over the weight ( ⁇ g) of 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt required for 50% inhibition of collagenase.
- the compound 6,6'-[ureylenebis(m-phenylenecarbonylimino]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt has been established as an inhibitor of the degradation of collagen in U.S. Pat. No. 4,297,372.
- An ID 50 collagenase ratio of one indicates that the compound is as efficient as the reference compound in inhibiting collagen degradation. A value greater than one indicates that the test compound is less active.
- the amount of 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt bound is determined by washing away the unbound radioactive compound and counting CPM (counts per minute) of the insoluble tooth powder/ 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt complex.
- the assay may be used to determine the ability of a competing analog of 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt to inhibit binding in the following manner: 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt and a non-radioactive analog thereof were incubated with tooth powder.
- the inhibiting effect of the test compound on binding compared to non-radioactive 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt was determined as follows: A one mg amount of tooth powder was incubated in one ml of phosphate buffered saline (PBS) with 10 ⁇ g of 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt and varying dose amounts (ranging from 0 to 2 mg) of the same cold (non-radioactive) compound.
- PBS phosphate buffered saline
- the unbound radioactive compound was washed away and the amount of radioactivity bound to the tooth powder was determined for each dose by counting (CPM).
- the dose in ⁇ g of cold compound required to decrease the amount of radioactive agent by 50% (ID 50 ) was determined.
- varying amounts of the test compound were substituted for cold 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt in the above assay and the ID 50 for this compound was determined.
- An ID 50 binding ratio of one indicates that the compound is as efficient as the reference compound in competition for binding sites in tooth powder. Values greater than one indicate the compound is less efficient than the reference compound.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention concerns novel compounds useful in compositions and methods for preventing the attachment of dental plaque to the surfaces of the teeth of mammals and as inhibitors of connective tissue destruction. The compounds of this invention comprise certain [ureylenebis-(phenylenesulfonylimino)]bis[hydroxynaphthalenesulfonic acids] and salts thereof which may be combined with pharmaceutically acceptable carriers or diluents to be administered in the form of conventional pharmaceutical compositions.
Description
1. Field of the Invention
The present invention relates to certain [ureylenebis(phenylenesulfonylimino)]bis[hydroxynaphthalenesulfonic acids] and salts thereof, which are novel compounds useful as dental antiplaque agents and as inhibitors of connective tissue destruction.
2. Description of the Prior Art
Abnormal destruction of connective tissue by collagenase and/or neutral proteases causes tissue damage and/or tissue dysfunction. In these conditions an inhibitor of connective tissue destruction acting directly or indirectly would be useful in preventing, retarding, or reversing tissue damage and/or collagen diseases.
The term connective tissue refers to a matrix of at least three protein molecules, namely collagen, proteoglycan and elastin. These molecules play an important role in the structural integrity of normal tissues. Collagen, the most abundant protein in the body occupies a central position in the connective tissue matrix [Biochemistry of Collagen, Ed. G. N. Ramachandran and A. H. Reddi, Academic Press, New York (1976); P. Bornstein, Ann. Rev. Biochem., 43, 567 (1974); J. Fessler and L. Fessler, Ann. Rev. Biochem., 47, 129 (1978)].
Collagen is, for example, the main structural component of the oral tissue (periodontal ligament, alveolar bone, gingiva, and cementum) [Fullmer, et al., J. Dental Research, 48, 646 (1969)]. Collagen amounts to 40% of cartilage protein, 90% of bone protein, and over 90% of dry dermis. Articular cartilage, the resilient tissue that covers the articulating extremities in synovial joints, consists of collagen fibers that are intimately meshed in a hydrated gel of proteoglycan.
Proteoglycan, as it exists in cartilage, is a molecule in which sulfated polysaccharide chains are covalently linked to a protein backbone [Dynamics of Connective Tissue Macromolecules, Ed. P. M. Burleigh and A. R. Poole, North Holland, Amsterdam (1975)].
Elastin is a major connective tissue component of pulmonary structure [Elastin and Elastic Tissue, Ed. L. B. Sandberg, W. R. Gray, and C. Franzblau, Plenum Press, New York (1977)]. The breadkown of elastin of pulmonary connective tissue is considered the primary event in pulmonary emphysema [A. Janoff in "Proteases and Biological Control", Cold Spring Harbor Conference on Cell Proliferation, 2, 603 (1975)].
Degradation of fibrous collagen is initiated by a combination of neutral proteases and tissue collagenase as an integral part of a complex immunopathological process which results in the loss of collagen from normal tissue. Under normal conditions cellular mechanisms maintain a careful balance between the rates of collagen synthesis and degradation. However, in certain pathological conditions, the ensuing elevated levels of neutral proteases and collagenase can result in rapid collagen degradation and tissue dysfunction. For example, in periodontal disease, the generated elevated levels of neutral proteases and collagenase in the gingival crevicular fluid rapidly degrade the fibrous collagen supporting the teeth. Periodontal pockets result ultimately from collagen degradation and, as these pockets deepen, support of the teeth is lost and alveolar bone is resorbed [K. Ohlsson, I. Ohlsson, and G. I. Basthall, Acta Odontol. Scand., 32, 51 (1974); L. M. Golub, S. Kenneth, H. McEwan, J. B. Curran, and N. S. Ramamurthy, J. Dental Research, 55, 177 (1976); L. M. Golub, J. E. Stakin and D. L. Singer, J. Dental Research, 53, 1501 (1974); L. M. Wahl, S. M. Wahl, S. E. Mergenhagen, and G. R. Martin, Proc. Natl. Acad. Sci. U.S., 71, 3598 (1974); Science, 187, 261 (1975)].
In arthritic conditions such as in rheumatoid arthritis, septic arthritis, and osteoarthritis, elevated degradation of collagen and proteoglycan initiate rapid destruction of articular tissue [J. M. Evanson, J. J. Jefferey, and S. M. Krane, Science, 158, 499 (1967); E. D. Harris, D. R. Dibona and S. M. Krane, J. Clin. Invest., 48, 2104 (1969); E. D. Harris in Rheumatoid Arthritis, Medcom. Press, N.Y. (1974); Z. Werb, C. L. Mainardi, C. A. Vater, and E. D. Harris, New Eng. J. Med., 296, 1017 (1977); J. M. Dayer, R. G. Russell, and S. M. Krane, Science, 195, 181 (1977); E. D. Harris, C. A. Vater, C. L. Mainardi, and Z. Werb, Agents and Actions, 8, 35 (1978); D. E. Woolley, E. D. Harris, C. L. Mainardi, and C. E. Brinkerhoff, Science, 200, 773 (1978); E. D. Harris, C. S. Faulkner, F. E. Brown, Clin. Orthoped., 110, 303 (1975); M. G. Ehrlich, H. J. Mankin, H. Jones, R. Wright, and C. Crisper, J. Bone Jt. Surg., 57A, 565 (1975); S. Gordon, W. Newman, and B. Bloom, Agents and Action, 8, 19 (1978); "Mechanisms of Tissue Injury With Reference to Rheumatoid Arthritis", Ed. R. J. Perper, Ann. N. Y. Acad. Sci., 256, 1-450 (1975)].
Increased collagen degradation in bone can result in abnormal bone destruction as in osteoporosis [C. G. Griffith, G. Nichols, J. D. Asher, and B. Flannagan, J. Am. Med. Assoc., 193, 91 (1965); B. Gardner, H. Gray, and G. Hedyati, Curr. Top. Surg. Res., 2, 175 (1970); B. Gardner, S. Wallach, H. Gray, and R. K. Baker, Surg. Forum, 22, 435 (1971)]. Collagenase activity has also resulted in tissue damage in cholesteatoma [M. Abramson, R. W. Schilling, C. C. Huang, and R. G. Salome, Ann. Otol. Rhinol. Faryngol., 81, 158 (1975); M. Abramson and C. C. Huang, Larynogoscope, 77, 1 (1976)]. In corneal ulcerations that progress to loss of corneal integrity and function, collagenase has been implicated as a direct factor in corneal destruction [S. I. Brown, C. W. Hook, and N. P. Tragakis, Invest. Ophthamol., 11, 149 (1972); M. B. Berman, C. H. Dohlman, P. F. Davison, and M. Ghadinger, Exptl. Eye Res., 11, 225 (1971)]. Elevated levels of collagenase have also been observed in patients with epidermolysis bullosa and a group of related genetic diseases of the skin [E. A. Bauer, T. G. Dahl, and A. Z. Eisen, J. Invest. Dermatology, 68, 119 (1977)].
Increased breakdown of elastin of the lung tissue by neutral proteases (elastase) may contribute to the lesions in pulmonary emphysema [I. Mandel, T. V. Darmle, J. A. Frierer, S. Keller, and G. M. Turino in Elastin and Elastic Tissue, Ed. L. B. Sandberg, W. R. Gray, and C. Franzblau, Plenum Press, N.Y., p 221 (1977)].
A variety of substances, both naturally occurring and synthetically prepared, have been found to be inhibitors of connective tissue destruction, e.g., inhibitors of collagen degradation, that is as collagenase inhibitors. Such substances include, for example, ethylenediaminetetraacetate, 1,10-phenanthroline, cysteine, dithiothreitol and sodium auriothiomalate [D. E. Woolley, R. W. Glanville, D. R. Roberts, and J. M. Evanson, Biochem. J., 169, 265 (1978); S. Seifter and E. Harper, Chap. 18, "The Collagenases" in The Enzymes (3rd. Edition), 3, 649-697, Ed. by P. D. Boyer, Academic Press, N.Y. (1971)].
In the eye, a number of studies using collagenase inhibitors directly applied to corneal ulcerations have been reported. Calcium ethylenediaminetetraacetate and acetylcysteine reduce the frequency of ulceration in the alkali burned rabbit [M. Berman and C. Dohlman, Arch. Ophthamol., 35, 95 (1975)]. Both cysteine and acetylcysteine have been effective in the treatment of acute and chronic corneal ulceration in the human, although the latter compound was preferred because of its greater stability [S. I. Brown, N. P. Tragakis, and D. B. Pease, Am. J. Ophthalmol., 74, 316 (1972); M. Berman in Trace Components of Plasma: Isolation and Clinical Significance, 7th Annual Red Cross Symposium, p 225, Alan R. Liss, Inc., N.Y. (1976)].
Naturally occurring collagenase inhibitors include the serum components α2 -macroglobulin and β1 -anticollagenase [D. E. Woolley, R. W. Glanville, D. R. Roberts and J. M. Evanson, Biochem. J., 169, 265 (1978)].
The deposition of dental plaque on teeth is considered to be a precursor to dental caries, gingivitis and periodontal disease. Therefore methods and compositions useful for the prevention or inhibition of dental plaque formation on teeth are considered to be of major potential therapeutic importance.
Dental caries which always begin on the external surfaces of the teeth may be initiated by oral acidogenic bacteria which include Lactobacillis acidophilus and Streptococci, e.g., Streptococcus mutans, and yeasts capable of producing a pH of 5.5 or lower. Fermentable dietary carbohydrates serve as substrates for the microbial enzyme systems leading to the production of acidic metabolic products such as lactic, acetic, formic and butyric acids. Adherence of cariogenic bacteria such as Streptococcus mutans, and the like, to tooth enamel and their aggregation and colonization to dental plaque are prerequisites to the formation of carious lesions. Sucrose, cell wall polysaccharides, pellicle components of saliva and calcium, participate in the formation of the lesion. Colonization on the tooth surface may serve as an area favorable to the production of the acidic metabolic products hereinabove described, providing protection from the buffering action of the saliva and causing the dissolution of the enamel in the vicinity of the plaque area resulting in decalcification. Some proteolytic action on the organic structure may also take place.
Gingivitis, which is an inflammation of the gums characterized by congested, red and swollen gingivae, frequently may occur due to dental calculus as the sole cause.
Periodontitis, the most common form of periodontal disease is characterized by inflammatory tissue changes usually due to local irritation, which local causes include irritation resulting from calcareous deposits on the teeth.
In theory, dental caries can be prevented by eliminating cariogenic bacteria, especially Streptococcus mutans, from the mouth or by increasing the resistance of enamel to acid and/or the adherence of S. mutans to its surface.
Agents that bind to tooth components have, at least on a theoretical basis, a utility in the treatment of dental diseases [S. Hamada and H. D. Slade, Microbiol. Rev., 44, 331 (1980)]. Support of this view is derived from results obtained with chlorohexidine [G. Rolla, H. Loe and C. R. Schiott, Arch. Oral Biol., 16, 1109 (1971)]. These studies have shown that chlorohexidine, an antibacterial agent, binds to pellicle and/or tooth components and this binding may contribute, at least in part, to its long acting antigingivitis properties.
Fluoride, a known anticaries agent, is known to protect human tooth enamel from dissolution. Mechanistic studies indicate that fluoride binds to enamel and is incorporated into the hydroxyapatite fraction of the enamel. The resulting fluoroapatite is relatively resistant to acid.
U.S. Pat. No. 2,687,436 discloses substituted 3-(2-naphthyl)cyclohexanes useful in the treatment of collagen diseases. British Pat. Nos. 856,357 and 1,246,141, disclose 2-aryl-hexahydro-quinolizines and 1-hydroxylpraline derivatives, respectively, useful for treating diseases affecting connective tissue. The closest known structurally related compound to those of the present invention and disclosed as having collagenase inhibiting activity is found in Thromb. Res. 1977, 10(4), 605-11 wherein the trypanocidal agent trypan blue is reported as inhibiting the activity of collagenase, or a proteinase contaminant in the collagenase preparation. It is interesting, however, that in this same article, the ureide Suramin is reported as not inhibiting the action of collagenase. Ureides similar to those of the present invention, but not disclosed as inhibitors, are found in Journal of the Chemical Society, 3068 (1927), and in U.S. Pat. Nos. 1,218,654 and 1,308,071. The generic disclosure of the '071 patent encompasses a vast number of ureides and with proper selection, among the many possible variables, some of the compounds of this invention may be encompassed within this broad generic disclosure. However, such disclosure by itself does not anticipate or render obvious the invention claimed herein.
While some compounds may inhibit the destructive effect of collagenase on connective tissue by acting directly on collagenase itself, other compounds may inhibit such destruction by coating, binding or competing with sights on the connective tissue in such a manner as to prevent collagenase from attacking it. The present invention, however, is not to be restricted or limited to any particular mechanism or mode of action. Suffice it to say, that the compounds of this invention have utility as inhibitors of connective tissue destruction albeit in whatever manner or mode.
This invention is concerned with the novel C-substituted naphthalenemonosulfonic ureides which may be represented by Formula I: ##STR1## wherein A is hydrogen or a pharmaceutically acceptable salt cation; B is hydrogen, lower(C1 -C6)alkanoyl or alkali metal; and R is hydrogen or lower(C1 -C3)alkyl.
A preferred form of the present invention is concerned with those ureides wherein neither the R nor the NH--group are ortho to the fixed position of the sulfoxamido group (--NHSO2 --) in the bridgehead and such ureides may be represented by Formula II, III and IV: ##STR2## wherein A, B and R are as defined with reference to Formula I.
By pharmacologically acceptable salt cation is meant an alkali metal; an alkaline earth metal; ammonium; primary amine, e.g., ethylamine; secondary amine, e.g., diethylamine or diethanolamine; tertiary amine, e.g., pyridine, triethylamine or 2-dimethylaminomethyldibenzofuran; aliphatic amine, e.g., decamethylenediamine; or aromatic amine.
The novel [ureylenebis(phenylenesulfonylimino)]-bis[hydroxynaphthalenesulfonic acids] and salts thereof of the present invention have been found to bind to various tooth components and also to inhibit the deposition of dental plaque onto the teeth of mammals.
The [ureylenebis(phenylenesulfonylimino)]bis-[hydroxynaphthalenesulfonates] of this invention are substantially soluble in water or water/organic solvent vehicles and are applied to teeth by various means from different dentifrice formulations.
While the mechanism of action of these sulfonated derivatives in retarding plaque desposition is not known with certainty, the present invention is not to be restricted or limited to any particular mechanism or mode.
Representative compounds encompassed within this invention include, for example, 6,6'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(p-phenylenesulfonylimino) ]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(3-methyl-4,1-phenylenesulfonyl)imino]]bis [4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino) ]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino) ]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis-[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]-bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylene-bis(p-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylene-bis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylene-bis(m-phenylenesulfonylimino)]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(p-phenylenesulfonylimino) ]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(m-phenylenesulfonylimino) ]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(p-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]-bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]-bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(m-phenylenesulfonylimino)]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(p-phenylenesulfonylimino)]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis](6-methyl-3,1-phenylenesulfonyl)imino]]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis](3-methyl-4,1-phenylenesulfonyl)imino]]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(m-phenylenesulfonylimino)]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(p-phenylenesulfonylimino)]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis [8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(3 -methyl-4,1-phenylenesulfonyl)imino]]bis [8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(m-phenylenesulfonylimino)]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-ureylenebis(p-phenylenesulfonylimino)]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(m-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(p-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalensulfonic acid], disodium salt; 7,7'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis-[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt, 6,6'-ureylenebis(m-phenylenesulfonylimino)]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(p-phenylenesulfonylimino)]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis [8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6methyl-3,1-phenylenesulfonyl)imino]]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis(p-phenylenesulfonylimino)]bis [4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulfonylimino)]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis [(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis-[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis](3-methyl-4,1-phenylenesulfonyl)imino]]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(6-methyl-3,1-phenylensulfonyl)imino]]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis](6-methyl-3,1-phenylenesulfonyl)imino]]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis(m-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis(p-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalensulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylensulfonylimino0]bis[8-hydroxy-1-naphthalensulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis-[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[8-hydroxy-1-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(m-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis((p-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6' -[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(3-methyl-4,1-phenylensulfonyl)imino]]bis(1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(m-phenylenesulfonylimino)]bis [4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-2-napththalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 2,2'-[ureylenebis(m-phenylenesulfonylimino) ]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 2,2'-[ureylenebis(p-phenylenesulfonylimino)]bis[5hydroxy-1-naphthalenesulfonic acid], disodium salt; 2,2'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 2,2'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulfonylimino)]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[1-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[4 -hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4hydroxy-2-napththalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis](6-methyl-3,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[4-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[5-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis(m-phenylenesulfonylimino)]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis(p-phenylenesulfonylimino)]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 1,1'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[8-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[3-hydoxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[3-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[3-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[3-hydroxy- 2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[6-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[6-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[6-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[6-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulfonylimino)]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulfonylimino)]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(m-phenylenesulfonylimino)]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(p-phenylenesulfonylimino)]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-ureylenebis(m-phenylenesulfonylimino]bis]2-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[2-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[2-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[2-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(m-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis(p-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 8,8'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 5,5'[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4' -[ureylenebis[(3-methyl-4,1- phenylenesulfonyl)imino]]bis[7-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonyl-imino)]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[7-hydroxy-1naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(m-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis(p-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 7,7'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis(m-phenylenesulfonylimino)]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis(p-phenylenesulfonylimino)]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[7-hydroxy-1-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(m-phenylenesulfonylimino)]bis[3-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis(p-phenylenesulfonylimino)]bis-[3-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(6-methyl-3,1- phenylenesulfonyl)imino]]bis[3-hydroxy-2-naphthalenesulfonic acid], disodium salt; 6,6'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[3-hydroxy-2-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis(m-phenylenesulfonylimino)]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis(p-phenylenesulfonylimino)]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 3,3'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[6-hydroxy-1naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[6-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1- phenylenesulfonyl)imino]]bis[6-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis]6-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(m-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis(p-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis [3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 5,5'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebisbis(p-phenylenesulfonylimino)]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[6-hydroxy-2-naphthalenesulfonic acid], disodium salt; 4,4'-[ureylenebis(m-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid[, diacetate (diester); 4,4'-[ureylenebis(p-phenylenesulfonylimino)]bis[3-hydroxy-1-naphthalenesulfonic acid], diacetate (diester); 4,4'-[ureylenebis[(6-methyl-3,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], diacetate (diester); 4,4'-[ureylenebis[(3-methyl-4,1-phenylenesulfonyl)imino]]bis[3-hydroxy-1-naphthalenesulfonic acid], diacetate (diester); 6,6'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]tetrasodium salt; 6,6'-[ureylenebis(m-phenylenesulfonylimino)]bis[4-hydroxy-2 -naphthalenesulfonic acid]tetrasodium salt; 6,6'-[ureylenebis(4-methyl-3,1-phenylene)sulfonylimino]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt; and 6,6'-[ureylenebis(3-methyl-4,1-phenylene)sulfonylimino]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt.
This invention is also concerned with a method of inhibiting connective tissue destruction in a warm-blooded animal which comprises administering to said animal an effective inhibiting amount of a compound encompassed within Formulae I, II, III or IV. Moreover, this invention is concerned with a method of inhibiting the degradation sequelae of collagenase activity in a body fluid, such as crevicular fluid, synovial fluid and the like, which comprises subjecting body fluid collagenase to the action of an effective collagenase inhibiting amount of a compound encompassed within the above formulae. Body fluid can include blood, plasma, serum, synovial fluid, crevicular fluid, ocular fluid, etc., containing collagenase. The method of use aspect of this invention is further concerned with a method of inhibiting the action of collagenase in a warm-blooded animal which comprises internally administering to said animal an effective collagenase inhibiting amount of a compound encompassed with the above formulae.
A further method of use aspect of the present invention is concerned with a method for inibiting and preventing the deposition of dental plaque onto the surfaces of the teeth of warm-blooded animals, mainly, the deposition of dental plaque onto human teeth, which comprises applying the potential plaque barrier [ureylenebis-(phenylenesulfonylimino)]bis[hydroxynaphthalenesulfonic acids] and salts thereof of the present invention, which are substantially soluble in water or water/organic solvent vehicles, in the form of various dentifrice formulations such as pastes, ointments, creams, lotions, gels, powders, buccal tablets, lozenges, tooth paste, rinses and the like or other oral hygienic procedures.
Since the compounds of the present invention find utility as inhibitors of connective tissue destruction or as collagenase inhibitors in body fluids, as such they may be useful in ameliorating or preventing those pathological reactions resulting from the functioning of collagenase, and in the therapeutic treatment of warm-blooded animals having connective tissue disorders such as periodontal diseases and diseases of the teeth, osteoporosis, osteolysis, Paget's disease, hyperparathyroidism of renal failure, rheumatoid arthritis, septic arthritis, osteoarthritis, gout, acute synovitis, scleroderma, posoriasis, epidermolysis bullosa, keloids, blisters, cholesteatoma of the ear, and corneal ulceration. The compounds of the present invention may also be useful in those pathological states where excessive activity of neutral proteases causes tissue damage.
The compounds of the present invention may be prepared according to the following Flowchart A. ##STR3##
With reference to Flowchart A, a substituted-amino-naphthalenesulfonic acid (1) is dissolved in water, made basic with any suitable base such as, for example, an alkali acetate or alkali metal carbonate reacted with an alkali acetate such as sodium acetate, filtered and reacted under an inert atmosphere, e.g., nitrogen, with an excess of substituted nitrobenzenesulfonyl chloride (2), giving a substituted nitrobenzenesulfonamido-substituted -naphthalenesulfonic acid (3). This nitro derivative (3) is then hydrogenated in the presence of a suitable catalyst, giving the corresponding amine derivative (4). The amine (4) is dissolved in a basic solution of pyridine and water and then phosgenated. The final ureide product (5) is extracted from conventional organic solvents such as ethanol or ether. The resulting compound may be converted to its salt in a known manner.
The following Examples will serve to illustrate the invention in more detail and should not be construed to limit the scope of the invention in any way.
A suspension of 11.95 g of 6-amino-4-hydroxy-2-naphthalenesulfonic acid in 200 ml of water was adjusted to pH 8.0 with aqueous 5N sodium hydroxide, then 12.17 g of sodium acetate trihydrate was added to the stirred mixture followed by 15.06 g of p-nitrobenzenesulfonyl chloride. The mixture was stirred vigorously under nitrogen at room temperature for 16 hours producing a yellow solid. The mixture was filtered and the solid was washed with water, ethanol and then ether and dried in vacuo and gave 12.07 g of 4-hydroxy-6-p-nitrobenzenesulfonamido-2-naphthalenesulfonic acid sodium salt as a yellow solid.
A suspension of 2.0 g of 4-hydroxy-6-p-nitrobenzenesulfonamido-2-naphthalenesulfonic acid sodium salt in about 200 ml of water was converted to a solution by the addition of sufficient 10N sodium hydroxide. The solution was filtered and to the filtrate was added 2.8 g of 10% palladium-on-carbon catalyst. The mixture was hydrogenated in a Parr shaker until no further hydrogen was taken up. The reaction mixture was filtered through diatomaceous earth and the filter was washed with water. The filtrate and wash were combined and acidified with concentrated hydrochloric acid and gave a gum. The gum was separated and triturated with ethanol. Filtration gave 3.0 g of the desired product as a grey solid.
A 4.0 g amount of 4-hydroxy-6-sulfanilamido-2-naphthalenesulfonic acid (prepared as described in Example 1) was suspended in 90 ml of water and 2.14 ml of 5N sodium hydroxide was added to yield a solution. The solution was filtered and 11.0 ml of pyridine was added to the filtrate. Phosgene was passed into the filtrate at 18°-28° C. (ice bath cooling) with vigorous stirring giving a gummy material. Phosgenation was continued until the mixture was strongly acidic. Then 5N sodium hydroxide was added again until solution was achieved, 11 ml of pyridine was added and the mixture was rephosgenated. The supernatant was decanted and the residual gummy material was triturated with water. The resulting solid was collected by filtration and air dried. The solid was triturated with ethanol, filtered, and washed with ethanol, then ether and dried to give 3.0 g of a pink solid.
The solid was suspended in water and 5N sodium hydroxide was added to achieve solution at a total volume of about 30 ml. This solution was added with vigorous stirring to ethanol:ether (2:1). The precipitate formed was collected by filtration, washed with ether and dried and gave 1.75 g of pink solid.
The above solid was dissolved in 20 ml of water and adjusted to pH 6.0 with acetic acid. This solution was poured slowly into 360 ml of ethanol:ether (1:1) with vigorous stirring. The mixture was stirred for 30 minutes at room temperature then filtered. The solid was washed with ethanol:ether (2:1), then ether and dried to give 920 mg of the product of the Example as a pink solid.
______________________________________ Preparation of Compressed Tablet Ingredient mg./Tablet ______________________________________ Active Compound 0.5-500 Dibasic Calcium Phosphate N.F. qs Starch USP 40 Modified Starch 10 Magnesium Stearate USP 1-5 ______________________________________
______________________________________ Preparation of Compressed Tablet - Sustained Action Ingredient mg./Tablet ______________________________________ Active Compound as Aluminum 0.5-500 (as acid Lake*, Micronized equivalent) Dibasic Calcium Phsophate N.F qs Alginic Acid 20 Starch USP 35 Magnesium Stearate USP 1-10 ______________________________________ *Complement inhibitor plus aluminum sulfate yields aluminum complement inhibitor. Complement inhibitor content in aluminum lake ranges from 5-30%.
______________________________________ Preparation of Hard Shell Capsule Ingredient mg./Capsule ______________________________________ Active Compound 0.5-500 Lactose, Spray Dried qs Magnesium Stearate 1-10 ______________________________________
______________________________________ Preparation of Oral Liquid (Syrup) Ingredient % W/V ______________________________________ Active Compound 0.05-5 Liquid Sugar 75.0 Methyl Paraben USP 0.18 Propyl Paraben USP 0.02 Flavoring Agent qs Purified Water qs ad 100.0 ______________________________________
______________________________________ Preparation of Oral Liquid (Elixir) Ingredient % W/V ______________________________________ Active Compound 0.05-5 Alcohol USP 12.5 Glycerin USP 45.0 Syrup USP 20.0 Flavoring Agent qs Purified Water qs ad 100.0 ______________________________________
______________________________________ Preparation of Oral Suspension (Syrup) Ingredient % W/V ______________________________________ Active Compound as Aluminum 0.05-5 Lake, Micronized (acid equivalent) Polysorbate 80 USP 0.1 Magnesium Aluminum Silicate, 0.3 Colloidal Flavoring Agent qs Methyl Paraben USP 0.18 Propyl Paraben USP 0.02 Liquid Sugar 75.0 Purified Water qs ad 100.0 ______________________________________
______________________________________ Preparation of Injectable Solution Ingredient % W/V ______________________________________ Active Compound 0.05-5 Benzyl Alcohol N.F. 0.9 Water for Injection qs ad 100.0 ______________________________________
______________________________________ Preparation of Injectable Oil Ingredient % W/V ______________________________________ Active Compound 0.05-5 Benzyl Alcohol 1.5 Sesame Oil qs ad 100.0 ______________________________________
______________________________________ Preparation of Intra-Articular Product Ingredient Amount ______________________________________ Active Compound 2-20 mg. NaCl (physiological saline) 0.9% Benzyl Alcohol 0.9% Sodium Carboxymethylcellulose 1-5% pH adjusted to 5.0-7.5 Water for Injection qs ad 100% ______________________________________
______________________________________ Preparation of Injectable Depo Suspension Ingredient % W/V ______________________________________ Active Compound 0.05-5 (acid equivalent) Polysorbate 80 USP 0.2 Polyethylene Glycol 4000 USP 3.0 Sodium Chloride USP 0.8 Benzyl Alcohol N.F. 0.9 HCl to pH 6-8 qs Water for Injection qs ad 100.0 ______________________________________
______________________________________ Preparation of Dental Paste Ingredient % W/V ______________________________________ Active Compound 0.05-5 Zinc Oxide 15 Polyethylene Glycol 4000 USP 50 Distilled Water qs ad 100 ______________________________________
______________________________________ Preparation of Dental Ointment Ingredient % W/W ______________________________________ Active Compound 0.05-5 Petrolatum, White USP qs 100 ______________________________________
______________________________________ Preparation of Dental Cream Ingredient % W/W ______________________________________ Active Compound 0.05-5 Mineral Oil 50 Beeswax 15 Sorbitan Monostearate 2 Polyoxyethylene 20 Sorbitan 3 Monostearate Methyl Paraben USP 0.18 Propyl Paraben USP 0.02 Distilled Water qs 100 ______________________________________
______________________________________ Preparation of Topical Cream Ingredient % W/W ______________________________________ Active Compound 0.05-5 Sodium Lauryl Sulfate 1 Propylene Glycol 12 Stearyl Alcohol 25 Petrolatum, White USP 25 Methyl Paraben USP 0.18 Propyl Paraben USP 0.02 Purified Water qs 100 ______________________________________
______________________________________ Preparation of Topical Ointment Ingredient % W/W ______________________________________ Active Compound 0.05-5 Cholesterol 3 Stearyl Alcohol 3 White Wax 8 Petrolatum, White USP qs 100 ______________________________________
______________________________________ Preparation of Spray Lotion (Non-aerosol) Ingredient % W/W ______________________________________ Active Compound 0.05-5 Isopropyl Myristate 20 Alcohol (Denatured) qs 100 ______________________________________
______________________________________ Preparation of Buccal Tablet Ingredient g./Tablet ______________________________________ Active Ingredient 0.00325 6 × Sugar 0.29060 Acacia 0.01453 Soluble Starch 0.01453 F.D. & C. Yellow No. 6 Dye 0.00049 Magnesium Stearate 0.00160 0.32500 ______________________________________
The final tablet will weigh about 325 mg. and may be compressed into buccal tablets in flat faced or any other tooling shape convenient for buccal administration.
______________________________________ Preparation of Lozenge Ingredient g./Lozenge ______________________________________ Active Ingredient 0.0140 Kompact ® Sugar (Sucrest Co.) 0.7138 6 × Sugar 0.4802 Sorbitol (USP Crystalline) 0.1038 Flavor 0.0840 Magnesium Stearate 0.0021 Dye qs Stearic Acid 0.0021 1.4000 ______________________________________
The ingredients are compressed into 5/8" flat based lozenge tooling. Other shapes may also be utilized.
______________________________________ Preparation of Gelled Vehicles Ingredient % W/W ______________________________________ Active Compound 9-11 Sodium Chloride 0.9-1.2 Buffer and Flavor qs -- Purified Water qs ad 100 Active Compound 0.005-9 Sodium Alginate 0.5-2 Buffer and Flavor qs -- Purified Water qs ad 100 Active Compound 0.005-9 Hydroxypropyl Cellulose 0.5-2 Buffer and Flavor qs -- Purified Water qs ad 100 Active Compound 0.005-9 Guar Gum 0.5-2 Buffer and Flavor qs -- Purified Water qs ad 100 ______________________________________
______________________________________ Preparation of Oral Mouth Rinse Ingredient % W/V ______________________________________ Active Compound 0.05-20 Alcohol U.S.P. 0-20 Sorbitol 1-30 Buffer and Flavor qs -- Polysorbate 80 0.1-3 Cetyl Pyridinium Chloride 0.025-0.20 Purified Water qs ad 100 ______________________________________
______________________________________ Preparation of Tooth Paste Ingredient % W/W ______________________________________ Active Compound 0.05-15 Glycerin 5-15 Sorbitol 5-15 Sodium Carboxymethylcellulose 0.5-2 Magnesium Aluminum Silicate 0.1-1 Carrageenin 0.25-2 Preservative qs -- Sodium Lauryl Sulfate 0.1-3 Calcium Carbonate 25-45 Flavor qs -- Purified Water qs ad 100 ______________________________________
______________________________________ Preparation of Dental Paste Ingredient % W/W ______________________________________ Active Compound 0.05-20 Carboxymethylcellulose 5-20 Pectin 5-20 Plastibase ® 20-70 Gelatin 5-20 ______________________________________
______________________________________ Preparation of Dental Ointment Ingredient % W/W ______________________________________ Active Compound 0.05-20 Polyethylene Glycol 4000 50-80 Polyethylene Glycol 400 10-40 ______________________________________
______________________________________ Preparation of Dental Powder for Brushing or for Use in Water Spray (e.g. Water Pik ® ) Ingredient % W/W ______________________________________ Active Compound 0.05-10 Flavor qs -- Wetting Agents qs -- Dextrin qs ad 100 ______________________________________
______________________________________ Preparation of Stick for Application to Gums Ingredient % W/W ______________________________________ Active Compound 0.05-10 Glycerin 5-10 Propylene Glycol 40-80 Sodium Stearate 6-10 Flavor qs -- Water 0-10 ______________________________________
______________________________________ Preparation of Periodontal Packing Paste Ingredient % W/W ______________________________________ Paste Part A Active Compound 0.05-20 Caprylic Acid 9.0 Lauric Acid 27.0 Ethylcellulose(100 cps.) 2.0 Polypale Resin* 39.0 Gum Elemi 4.0 Brominol** 4.0 Mica (powdered) 7.5 Chlorothymol 1.0 Zinc Acetate 2.0 Bay Oil(essential oil) 1.0 Ethanol 1.5 Paste Part B Magnesium Oxide 43.0 Zinc Oxide 21.0 Calcium Hydroxide 3.5 Copper Oxide 2.0 Mineral Oil, Heavy 26.0 Rosin Oil 3.0 Chlorothymol 1.4 Cumarin (flavor) 0.1 When equal parts of A and B are mixed together at 25° C. a hard mass is formed in about 3 minutes. ______________________________________ *Partially polymerized rosin (i.e. modified rosin) **Brominated olive oil
______________________________________ Preparation of Periodontal Packing Paste Ingredient % W/W ______________________________________ Part A (powder) Active Compound 0.05-20 Canada Balsam, Neutral 8.5 Rosin NF 8.5 Calcium Hydroxide 34.4 Zinc Oxide U.S.P. 46.0 Part B (Liquid Hardener) Eugenol 85.0 Turpentine Oil, Rectified 15.0 A mixture of three drops of Part B added to 130 mg of Part A produces a hard mass in about 2-3 minutes at 30° ______________________________________ C.
The compounds of this invention may be administered internally to a warm-blooded animal to inhibit connective tissue destruction or collagenase, such inhibition being useful in the amelioration or prevention of those reactions causing connective tissue damage. A range of doses may be employed depending on the mode of administration, the condition being treated and the particular compound being used. For example, for intravenous or subcutaneous use from about 5 to about 50 mg/kg/day, or every six hours for more rapidly excreted salts, may be used. For intra-articular use for large joints such as the knee, from about 2 to about 20 mg/joint per week may be used, with proportionally smaller doses for smaller joints. The dosage range is to be adjusted to provide optimum therapeutic response in the warm-blooded animal being treated. In general, the amount of compound administered can vary over a wide range to provide from about 1.5 mg/kg to about 100 mg/kg of body weight of animal per day. The usual daily dosage for a 70 kg subject may vary from about 100 mg to about 3.5 g. Unit doses can contain from about 0.5 mg to about 500 mg.
While in general the sodium salts of the acids of the invention are suitable for parenteral use, other salts may also be prepared, such as those of primary amines, e.g., ethylamine; secondary amines, e.g., diethylamine or diethanolamine; tertiary amines, e.g., pyridine or triethylamine or 2-dimethylaminomethyldibenzofuran, aliphatic diamines, e.g., decamethylenediamine; and aromatoic diamines, can be prepared. Some of these are soluble in water, others are soluble in saline solution, and still others are insoluble and can be used for purposes of preparing suspensions for injection. Furthermore, as well as the sodium salt, those of the alkali metals, such as potassium and lithium; of ammonia; and of the alkaline earth metals, such as calcium or magnesium, may be employed. It will be apparent, therefore, that these salts embrace, in general, derivatives of salt-forming cations.
In therapeutic use, the compounds of this invention may be administered in the form of conventional pharmaceutical compositions. Such compositions may be formulated so as to be suitable for oral or parenteral administration. The active ingredient may be combined in admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, i.e., oral or parenteral.
The compounds of this invention can be used in compositions such as tablets. Here, the principle active ingredient is mixed with conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums, or similar materials as non-toxic pharmaceutically acceptable diluents or carriers.
The tablets or pills of the novel compositions can be laminated or otherwise compounded to provide a dosage form affording the advantage of prolonged or delayed action or predetermined successive action of the enclosed medication. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids or mixtures of polymeric acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate and the like. A particularly advantageous enteric coating comprises a styrene maleic acid copolymer together with known materials contributing to the enteric properties of the coating. The tablet or pill may be colored through the use of an appropriate nontoxic dye, so as to provide a pleasing appearance.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration include suitable flavored emulsions with edible oils, such as, cottonseed oil, sesame oil, coconut oil, peanut oil, and the like, as well as elixirs and similar pharmaceutical vehicles. Sterile suspensions or solutions can be prepared for parenteral use. Isotonic preparations containing suitable preservatives are also desirable for injection use.
The compounds of the present invention may also be administered topically in the form of ointments, creams, lotions and the like, suitable for the treatment of connective tissue dependent dermatological disorders.
Moreover, the compounds of the present invention may be administered in the form of dental pastes, ointments, buccal tablets and other compositions suitable for application periodontally for the treatment of periodontitis and related diseases of the oral cavity.
The term dosage form as described herein refers to physically discrete units suitable as unitary dosage for warm-blooded animal subjects, each unit containing a predetermined quantity of active component calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle. The specification for the novel dosage forms of this invention are indicated by characteristics of the active component and the particular therapeutic effect to be achieved or the limitations inherent in the art of compounding such an active component for therapeutic use in warm-blooded animals as disclosed in this specification. Examples of suitable oral dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, cachets, teaspoonfuls, dropperfuls, ampules, vials, segregated multiples of any of the foregoing and other forms as herein described.
The inhibiting activity of a representative compound of the invention on the destruction of connective tissue has been demonstrated by the following identified test: (i) Collagenase Assay, Test Code 006--This test measures the ability of human skin fibroblast collagenase to degrade radiolabled native collagen fibrils. An active inhibitor inhibits the degradation of the collagen fibril.
(i) Collagenase Assay--Test Code 006
A collagenase assay was performed by a modification of the method of Harper, et al., Biochem., 10, 3035 (1971). In a typical assay (total volume of 0.45 ml), 100 μl of the activated enzyme was added to the 14 C-labeled collagen fibrils (250 μl) followed by 100 μl of 50 mM cacodylate, pH 7.4, containing 5 mM calcium chloride. After incubation at 37° C. for 16 hours, the tubes were centrifuged in a Beckman microfuge for five minutes at full speed. An aliquot (200 μl) of the supernatant, representing collagenase digestion products of the fibril, was assayed for radioactivity. The effect of the test compound on collagen degradation by collagenase was examined as follows:
Varying concentrations of the test compound (in distilled water) were added to the assay tubes containing active collagenase (total volume 450 μl) and after 16 hours the amount of radioactivity in the supernatant was determined. Appropriate blanks and trypsin controls were run in parallel.
Table I shows that a representative compound of the invention possesses the ability to inhibit collagen degradation. The result is expressed as an ID50 collagenase value which represents a ratio of the weight (μg) of the representative compound required for 50% inhibition of collagenase over the weight (μg) of 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt required for 50% inhibition of collagenase. The compound 6,6'-[ureylenebis(m-phenylenecarbonylimino]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt has been established as an inhibitor of the degradation of collagen in U.S. Pat. No. 4,297,372. An ID50 collagenase ratio of one indicates that the compound is as efficient as the reference compound in inhibiting collagen degradation. A value greater than one indicates that the test compound is less active.
TABLE I ______________________________________ Biological Activity (test conc.: 30 μg/ml) ID.sub.50 Collagenase Compound Ratio ______________________________________ 6,6'-[Ureylenebis( -p-phenylene- 1.73 sulfonylimino)]bis[4-hydroxy- 2-naphthalenesulfonic acid]- disodium salt ______________________________________
Binding Assay
It has been shown that 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt will bind to insoluble collagenous structures such as teeth, dentin, gingiva and the like. This binding is saturable and reversible.
Using (radioactive) 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt, an in vitro binding (competition) assay procedure has been established which involves an insoluble substrate such as tooth powder which will bind the 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt. The amount of 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt bound is determined by washing away the unbound radioactive compound and counting CPM (counts per minute) of the insoluble tooth powder/14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt complex. The assay may be used to determine the ability of a competing analog of 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt to inhibit binding in the following manner: 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt and a non-radioactive analog thereof were incubated with tooth powder. The inhibiting effect of the test compound on binding compared to non-radioactive 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt was determined as follows: A one mg amount of tooth powder was incubated in one ml of phosphate buffered saline (PBS) with 10 μg of 14 C-6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt and varying dose amounts (ranging from 0 to 2 mg) of the same cold (non-radioactive) compound. After 60 minutes at 37° C., the unbound radioactive compound was washed away and the amount of radioactivity bound to the tooth powder was determined for each dose by counting (CPM). The dose in μg of cold compound required to decrease the amount of radioactive agent by 50% (ID50) was determined. Then varying amounts of the test compound were substituted for cold 6,6'-[ureylenebis(m-phenylenecarbonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt in the above assay and the ID50 for this compound was determined.
An ID50 ratio provides a biological comparison of all compounds as established by use of the following equation: ##EQU1##
Results of this test on a representative compound of the present invention appear in Table II.
TABLE II ______________________________________ Compound ID.sub.50 Binding Ratio ______________________________________ 6,6'-[Ureylenebis( -p-phenylene- 1.55 sulfonylimino)]bis[4-hydroxy- 2-napthalenesulfonic acid]- disodium salt ______________________________________
An ID50 binding ratio of one indicates that the compound is as efficient as the reference compound in competition for binding sites in tooth powder. Values greater than one indicate the compound is less efficient than the reference compound.
Claims (12)
1. A compound of the formula: ##STR4## wherein A is hydrogen or a pharmaceutically acceptable salt cation; B is hydrogen, lower(C1 -C6)alkanoyl or alkali metal; and R is hydrogen or lower(C1 -C3)alkyl.
2. A compound according to claim 1 of the formula: ##STR5## wherein A is hydrogen or a pharmaceutically acceptable salt cation; B is hydrogen, lower(C1 -C6)alkanoyl or alkali metal; and R is hydrogen or lower(C1 -C3)alkyl.
3. A compound according to claim 1 of the formula: ##STR6## wherein A is hydrogen or a pharmaceutically acceptable salt cation; B is hydrogen, lower(C1 -C6)alkanoyl or alkali metal; and R is hydrogen or lower(C1 -C3)alkyl.
4. A compound according to claim 1 of the formula: ##STR7## wherein A is hydrogen or a pharmaceutically acceptable salt cation; B is hydrogen, lower(C1 -C6)alkanoyl or alkali metal; and R is hydrogen or lower(C1 -C3)alkyl.
5. The compound according to claim 1; 6,6'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt.
6. A composition of matter for the treatment of pathological reactions resulting from the functioning of collagenase or of connective tissue disorders, which comprises a compound as recited in claim 1 and a pharmaceutically acceptable carrier or diluent.
7. A composition of matter, as recited in claim 6, wherein the pharmaceutically acceptable carrier or diluent is an aqueous solution or an injectable solution.
8. A composition of matter for the topical treatment of pathological reactions resulting from the deposition of dental plaque or of connective tissue disorders which comprises a compound as recited in claim 1 and a pharmaceutically acceptable carrier or diluent adapted for topical administration.
9. A composition of matter, as recited in claim 8, wherein the pharmaceutically acceptable carrier or diluent is a gelled vehicle, a buccal tablet or a lozenge.
10. A dental preparation characterized in that said preparation contains as a topically effective, therapeutically active ingredient a compound as recited in claim 1.
11. A dental preparation, as recited in claim 10, wherein the preparation is a mouth rinse, a dental paste, a dental cream, a dental powder, a tooth paste, a periodontal packing paste, a periodontal packing powder or a dental stick.
12. The composition or preparation, as recited in claims 6, 7, 8, 9, 10 or 11 wherein said compound is 6,6'-[ureylenebis(p-phenylenesulfonylimino)]bis[4-hydroxy-2-naphthalenesulfonic acid]disodium salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/710,771 USH83H (en) | 1985-03-11 | 1985-03-11 | Dental antiplaque agents and inhibitors of connective tissue destruction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/710,771 USH83H (en) | 1985-03-11 | 1985-03-11 | Dental antiplaque agents and inhibitors of connective tissue destruction |
Publications (1)
Publication Number | Publication Date |
---|---|
USH83H true USH83H (en) | 1986-07-01 |
Family
ID=24855460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/710,771 Abandoned USH83H (en) | 1985-03-11 | 1985-03-11 | Dental antiplaque agents and inhibitors of connective tissue destruction |
Country Status (1)
Country | Link |
---|---|
US (1) | USH83H (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648390A (en) * | 1992-08-07 | 1997-07-15 | The United States Of America As Represented By The Secretary Of Agriculture | Repellents for ants |
US9498414B1 (en) | 2006-03-30 | 2016-11-22 | Janet M. Wehrli | System and method for reducing plaque on teeth |
US9833386B2 (en) | 2006-03-30 | 2017-12-05 | James D. Welch | Method of, and system for smoothing teeth |
US10092488B1 (en) | 2006-03-30 | 2018-10-09 | Janet M. Wehrli | System and method for reducing plaque on teeth |
US10342646B2 (en) | 2015-10-17 | 2019-07-09 | James D. Welch | Method of, and system for smoothing teeth |
US11103732B1 (en) | 2015-10-17 | 2021-08-31 | James D. Welch | Method of improving the condition of teeth |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1218654A (en) | 1914-12-17 | 1917-03-13 | Synthetic Patents Co Inc | Ureids and thioureids. |
US1308071A (en) | 1919-07-01 | |||
US2687436A (en) | 1952-01-28 | 1954-08-24 | Merck & Co Inc | Substituted 3-(2-naphthyl)-cyclohexane |
GB856357A (en) | 1958-03-24 | 1960-12-14 | Wm S Merrell Co | 2-aryl-hexahydro-quinolizines |
GB1246141A (en) | 1967-09-14 | 1971-09-15 | Paul Coirre | Improvements in or relating to -hydroxylproline derivatives |
US4131684A (en) | 1976-05-10 | 1978-12-26 | American Cyanamid Company | Complement inhibitors |
US4216164A (en) | 1976-05-10 | 1980-08-05 | American Cyanamid Company | Ureide inhibitors of connective tissue destruction |
US4216166A (en) | 1976-05-10 | 1980-08-05 | American Cyanamid Company | Nitro precursors to amine precursors to ureide inhibitors of connective tissue destruction |
US4216165A (en) | 1976-05-10 | 1980-08-05 | American Cyanamid Company | Amine precursors to ureide inhibitors of connective tissue destruction |
US4297372A (en) | 1978-12-20 | 1981-10-27 | American Cyanamid Company | Ureide inhibitors of connective tissue destruction |
-
1985
- 1985-03-11 US US06/710,771 patent/USH83H/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1308071A (en) | 1919-07-01 | |||
US1218654A (en) | 1914-12-17 | 1917-03-13 | Synthetic Patents Co Inc | Ureids and thioureids. |
US2687436A (en) | 1952-01-28 | 1954-08-24 | Merck & Co Inc | Substituted 3-(2-naphthyl)-cyclohexane |
GB856357A (en) | 1958-03-24 | 1960-12-14 | Wm S Merrell Co | 2-aryl-hexahydro-quinolizines |
GB1246141A (en) | 1967-09-14 | 1971-09-15 | Paul Coirre | Improvements in or relating to -hydroxylproline derivatives |
US4131684A (en) | 1976-05-10 | 1978-12-26 | American Cyanamid Company | Complement inhibitors |
US4216164A (en) | 1976-05-10 | 1980-08-05 | American Cyanamid Company | Ureide inhibitors of connective tissue destruction |
US4216166A (en) | 1976-05-10 | 1980-08-05 | American Cyanamid Company | Nitro precursors to amine precursors to ureide inhibitors of connective tissue destruction |
US4216165A (en) | 1976-05-10 | 1980-08-05 | American Cyanamid Company | Amine precursors to ureide inhibitors of connective tissue destruction |
US4297372A (en) | 1978-12-20 | 1981-10-27 | American Cyanamid Company | Ureide inhibitors of connective tissue destruction |
Non-Patent Citations (2)
Title |
---|
Balaban, I. E. and King, H., Journal of the Chemical Society, 3068 (1927). |
Moroz, L. A., Thromb. Res., 10(4), 605 (1977). |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648390A (en) * | 1992-08-07 | 1997-07-15 | The United States Of America As Represented By The Secretary Of Agriculture | Repellents for ants |
US6071973A (en) * | 1992-08-07 | 2000-06-06 | The United States Of America As Represented By The Secretary Of Agriculture | Repellent for ants |
US9498414B1 (en) | 2006-03-30 | 2016-11-22 | Janet M. Wehrli | System and method for reducing plaque on teeth |
US9833386B2 (en) | 2006-03-30 | 2017-12-05 | James D. Welch | Method of, and system for smoothing teeth |
US10092488B1 (en) | 2006-03-30 | 2018-10-09 | Janet M. Wehrli | System and method for reducing plaque on teeth |
US10342646B2 (en) | 2015-10-17 | 2019-07-09 | James D. Welch | Method of, and system for smoothing teeth |
US11103732B1 (en) | 2015-10-17 | 2021-08-31 | James D. Welch | Method of improving the condition of teeth |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5258371A (en) | Method to reduce connective tissue destruction | |
US4636382A (en) | Morpholino compounds and compositions | |
US4647452A (en) | Oral compositions of salicylamides and zinc salts for the synergistic inhibition of dental plaque | |
CA2083606A1 (en) | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use | |
KR970006891B1 (en) | Benzoyl amino phenoxy butanoic acid derivatives | |
CA2253997A1 (en) | Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives, processes for their preparation and pharmaceutical compositions comprising them | |
US4894221A (en) | Method of treating plaque using morpholine compounds | |
USH83H (en) | Dental antiplaque agents and inhibitors of connective tissue destruction | |
CA2137897A1 (en) | Biaromatic compounds derived from amides; pharmaceutical and cosmetic compositions containing the same and their uses | |
FR2487358A1 (en) | NEW DERIVATIVES OF LINCOMYCIN | |
US4599204A (en) | Oxalylamides useful as dental antiplaque agents and inhibitors of connective tissue destruction | |
US4297372A (en) | Ureide inhibitors of connective tissue destruction | |
US4216164A (en) | Ureide inhibitors of connective tissue destruction | |
NZ205254A (en) | Ng-alkanoylarginines:oral hygiene compositions | |
US4216165A (en) | Amine precursors to ureide inhibitors of connective tissue destruction | |
US4216166A (en) | Nitro precursors to amine precursors to ureide inhibitors of connective tissue destruction | |
US4391824A (en) | Ureylenebis (hydroxy naphthalenesulfonic acids) | |
US4275076A (en) | Substituted naphthoic acids | |
US4291169A (en) | Substituted naphthoic acids | |
AU548494B2 (en) | Substituted naphthoic acids | |
EP0013784B1 (en) | C-substituted naphthalenemonosulfonic ureides, process for their preparation and pharmaceutical compositions containing them | |
WO1982003550A1 (en) | Substituted naphthoic acids | |
IE47905B1 (en) | C-substituted naphthalenemonosulfonic ureides,process for their preparation and pharmaceutical compositions containing them | |
KR100603948B1 (en) | Peptide derivative, pharmaceutically acceptable salt thereof, process for producing the same, and use thereof | |
NZ196764A (en) | Hydroxynaphthoic acid ureides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |